NDAINTRAVENOUSINJECTABLE, LIPOSOMAL
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Clinical Trials (2)
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Started Jan 2021
Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
Started Jun 2013